Akorn Inc

Akorn — Merger or Acquisition (August 2013)

13 slides from Akorn's merger presentation, Aug 27, 2013

  1. Slide 1: Akorn, Inc. Sterile Ophthalmic and Injectable Pharmaceuticals

    Akorn, Inc. Nasdaq: AKRX August 2013 Sterile Ophthalmic and Injectable Pharmaceuticals

  2. Slide 2: Forward-looking statements disclaimer

    Title: disclaimer Other Placeholder: This presentation includes certain forward-looking statements regarding our views with respect to our business and our expected performance for future periods. These statements are intended as “forward-looking statements” under the Private Securities Litigation R

  3. Slide 3: A unique combination: anticipated transaction benefits

    Title: A unique combination Anticipated transaction benefits Creates a larger, more diversified specialty generics playerBuilds scale, breadth of products and dosage forms, enhances diversificationOver $500 million in combined company revenuesApproximately 40% accretive to non-GAAP earnings with syn

  4. Slide 4: Key transaction terms

    Title: Key transaction terms Purchase price $43.50 / share or $640 million equity value1 Cash/share mix All cash; debt financed Funding mix Fully-committed financing from JPMorgan Chase Bank, N.A. Time to accretion Immediately accretive Closing conditions Subject to customary closing conditions and

  5. Slide 5: Akorn's transformation

    Title: Akorn’s transformation Bolstered management team by adding expertise and experienceFocused on core competency in sterile manufacturingModernization and expansion of our manufacturing facilitiesInvested in R&D yielding a strong pipeline of products Through organic growth Through strategic Acqu

  6. Slide 6: Hi-Tech Business Segments

    Title: Hi-Tech Business Segments Other Placeholder: 6 Cough/coldNutritionalCosmetic productsPainNasal 56 products in a variety of dosage forms:Oral solutions and suspensionsTopical creams and ointments Nasal sprays and oticsSterile liquid ophthalmic, inhalation productsControlled substances TussiCap

  7. Slide 7: Strategic rationale

    Title: Strategic rationale Diversifies and strengthens Akorn’s product portfolio Hi-Tech offers products in additional niche categories: topicals, otics, nasal sprays, oral liquidsThe Health Care Products OTC product line provides additional breadth in the retail OTC marketProvides opportunity to pr

  8. Slide 8: Increased market opportunity

    ADDRESSABLE US MARKET 5.7X 18.7 X Hi-Tech Manufacturing Title: Increased market opportunity Source: IMS Health and company analysis AKorn Manufacturing Sterile Products:SolutionsOintmentsGelsInjectablesLiquidLyophilized Newly addressable with Hi-Tech Non-Sterile Products:Nasal spraysOral liquidsTopi

  9. Slide 9: Enhanced R&D Capabilities and pipeline

    Title: Enhanced R&D Capabilities and pipeline Akorn has 57 filings under review at the FDA as of 6/30/13 for an estimated market value of ~$5.4bnHi-Tech has a robust ANDA pipeline with:18 additional products are pending approval ($2.6bn market value) including sterile ophthalmic products, controlled

  10. Slide 10: Private Label Opportunity

    Title: Private Label Opportunity $500 million Estimated non-sterile OTC addressable market for private label creams, liquids, nasal sprays With the acquisition of AVR, Akorn has established itself as a player in the private label OTC market: Newly Accessible Mkt Source: Market value is based on IRI

  11. Slide 11: Summary

    @@@ | sumMmaRY

  12. Slide 12: A unique combination: anticipated transaction benefits

    Title: A unique combination Anticipated transaction benefits Creates a larger, more diversified specialty generics playerBuilds scale, breadth of products and dosage forms, enhances diversificationOver $500 million in combined company revenuesApproximately 40% accretive to non-GAAP earnings with syn

  13. Slide 13: Advancing the new vision

    CAKGRN a @ ADVANCING THE NEW VISION SS

Akorn — Merger or Acquisition (August 2013) on 6ix